Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys Healthcare Forum

Dimerix Limited ( (AU:DXB) ) has issued an update.

Dimerix Limited announced that CEO and Managing Director Dr Nina Webster will present at the Euroz Hartleys Healthcare Forum in Perth, providing an update on the company’s global Phase 3 ACTION3 trial of DMX-200 in FSGS kidney disease, including patient recruitment progress by country, the status of commercial partnering discussions, and the broader company growth strategy. The appearance at a specialist healthcare investor forum underscores Dimerix’s efforts to showcase late-stage clinical progress in a rare kidney disease with high unmet need, potentially strengthening its profile with investors and partners as it seeks to advance DMX-200 toward marketing approval and execute on its commercial and expansion plans.

The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.

More about Dimerix Limited

Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company focused on inflammatory diseases, particularly kidney conditions such as Focal Segmental Glomerulosclerosis (FSGS), and respiratory disease. Its lead Phase 3 product candidate, DMX-200, is being developed for FSGS and is supported by a patent portfolio potentially extending to 2042 and Orphan Drug Designation in the U.S., while a second candidate, DMX-700, targets respiratory indications. Both assets were discovered using the company’s proprietary Receptor-HIT platform, which enables rapid screening of receptor interactions to identify new drug opportunities.

Average Trading Volume: 1,263,914

Technical Sentiment Signal: Buy

Current Market Cap: A$306.2M

See more data about DXB stock on TipRanks’ Stock Analysis page.